Elevance Health (NYSE:ELV – Get Free Report) was upgraded by research analysts at StockNews.com from a “hold” rating to a ...

it is easy to disregard Elevance Health (NYSE:ELV). However, stock prices are usually driven by a company’s financial performance over the long term, which in this case looks quite promising.

We took advantage of Elevance Health's share price weakness in the fourth quarter and added modestly to our investment. Click ...

Elevance Health (NYSE:ELV – Get Free Report) had its price objective lowered by stock analysts at Wells Fargo & Company from $483.00 to $478.00 in a report issued on Tuesday,Benzinga reports. The ...

With its stock down 7.4% over the past three months, it is easy to disregard Elevance Health (NYSE:ELV). However, stock prices are usually driven by a company’s financial performance over the long ...

A collection of prominent healthcare interests were among the donors to President Donald Trump’s inaugural fund. | The pharma ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Neurosense Therapeutics Ltd. (NRSN – Research Report), ...

Elevance Health has a market capitalization of $90.56 billion. Buying $1000 In ELV: If an investor had bought $1000 of ELV stock 20 years ago, it would be worth $6,446.06 today based on a price of ...

Cantor Fitzgerald reaffirmed its Neutral stance on Humana (NYSE:HUM) stock, maintaining the price target at $290.00. The stock, currently trading at $257.34, has experienced a significant 11.4% ...